iRhythm Board Authorizes $200M Buyback Backed by Cash Flow
IRTC is trading near its 52-week low of $82.85 (7.0% above the low).
Summary
iRhythm's board approved a $200 million share repurchase authorization on November 10, roughly two-thirds the size of the company's market value and a meaningful chunk of its equity base. Management says it will fund the program from existing cash and operating cash flow, and frames it as confidence in the core business plus the newly acquired VitalConnect assets. The timing is notable: it lands days after Q3 revenue of $221.6M (up 14.9%) and a raised FY26 revenue guide, but also after the Zio MCT FDA submission slipped from 2026 into 2027. Buybacks are discretionary — no obligation to repurchase any amount, and the program can be suspended at any time — so the practical effect depends on execution pace rather than the headline authorization.
At the time of this announcement, IRTC was trading at $88.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $82.85 to $192.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.